ABT 652
Alternative Names: ABT-652Latest Information Update: 05 Nov 2023
At a glance
- Originator Abbott Laboratories
- Class Analgesics; Sleep disorder therapies
- Mechanism of Action Histamine H3 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetic neuropathies; Musculoskeletal pain; Sleep disorders
Most Recent Events
- 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
- 26 Jul 2012 Profile reviewed, separated combination therapy trial in ph table, changed Neur pain to Diab neur, added formulation for Diab pain, updated Inthought scores
- 26 Jul 2012 Abbott plans phase IIb trials for Pain